enzalutamide

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Salivary Cancer

Conditions

Salivary Cancer

Trial Timeline

Sep 14, 2016 → Jul 5, 2028

NCT ID

NCT02749903

About enzalutamide

enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Salivary Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02749903. Target conditions include Salivary Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05404139	Phase 2	Recruiting	May 24, 2023	Mar 1, 2026	Metastatic Prostate Cancer
NCT02749903	Phase 2	Active	Sep 14, 2016	Jul 5, 2028	Salivary Cancer
NCT02799745	Phase 2	Completed	Jun 9, 2016	Aug 28, 2020	Prostate Cancer
NCT02750358	Phase 2	Active	May 19, 2016	May 1, 2026	Breast Cancer
NCT02605863	Phase 2	Terminated	Jan 1, 2016	Feb 1, 2018	Bladder Cancer
NCT02384382	Phase 2	Completed	Nov 30, 2015	May 3, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02441517	Approved	Terminated	Oct 28, 2015	Mar 15, 2017	Metastatic Castration Resistant Prostate Cancer
NCT02507570	Phase 2	Completed	Sep 23, 2015	Jan 18, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02495974	Pre-clinical	Completed	Sep 8, 2015	Feb 8, 2019	Metastatic Castration Resistant Prostate Cancer
NCT02203695	Phase 2	Completed	Mar 28, 2015	Dec 31, 2022	Adenocarcinoma of the Prostate
NCT02288936	Phase 2	Completed	Feb 5, 2015	Jul 22, 2019	Hormone-refractory Prostate Cancer
NCT02669771	Pre-clinical	Completed	Nov 30, 2014	Nov 30, 2018	Castration-resistant Prostate Cancer
NCT02124668	Phase 2	Completed	Sep 23, 2014	May 25, 2017	Castration-Resistant Prostate Cancer
NCT03297385	Phase 2	Completed	Aug 28, 2014	Apr 1, 2017	Prostate Cancer
NCT02116582	Approved	Completed	May 23, 2014	Sep 29, 2017	Metastatic Castration-Resistant Prostate Cancer
NCT02099864	Phase 2	Completed	Feb 5, 2014	Jul 8, 2024	Castration-Resistant Prostate Carcinoma
NCT01977651	Approved	Completed	Sep 25, 2013	Jan 11, 2019	Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02138162	Phase 1	Completed	Aug 1, 2013	Mar 1, 2014	Severe Hepatic Impairment
NCT01889238	Phase 2	Completed	Jun 12, 2013	Jan 10, 2024	Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
NCT01663415	Phase 2	Withdrawn	Aug 1, 2012	Oct 1, 2014	Metastatic Castration-Resistant Prostate Cancer

Competing Products

11 competing products in Salivary Cancer

See all competitors

Product	Company	Stage	Hype Score
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Gefitinib	AstraZeneca	Phase 2	52
Goserelin Acetate + Pembrolizumab	Merck	Phase 2	52
Dovitinib	Novartis	Phase 2	52
Sacituzumab govitecan	Gilead Sciences	Phase 2	51
Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 2	51
Ipilimumab + Nivolumab	Bristol Myers Squibb	Phase 2	51
Darolutamide + Goserelin	Bayer	Phase 2	49
Ivonescimab	Summit Therapeutics	Phase 2	49
Cabozantinib	Ipsen	Phase 2	49
AVA6000	Avacta Group	Phase 1	25

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved